Investors

Investors

Our mission is not to just bring a new immunotherapy drug to the market, but to create a new multi-billion dollar biopharmaceutical industry that will eventually replace marginally effective and highly toxic cancer treatments with highly effective and minimally toxic immunotherapy products. Immunotherapy is the only treatment modality that has the technological capability to cure cancer. The immune system can locate and eliminate the last tumor cell, something that is not feasible for a surgeon’s scalpel, radiation or chemotherapy. Without this ability, the tumors recur and spread. There is no cure for metastatic cancer. In addition, the immune system has the special feature of memory. Once the immune system sterilizes the body of all disease, it remembers the cancer so that if the disease should return in the future, the immune system is capable of rising up and protecting against disease without any further treatment. Our goal is to fast track to FDA approval and revenues and then reinvest profits into research and development efforts that will eventually lead us to optimize our immunotherapy drugs in order to develop a cure for cancer in our lifetime.

Business Summary

Partnering Brochure

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more